Brief: Fusion Pharmaceuticals Announces Presentation Of Interim Data From The Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 At The AACR Annual Meeting 2024
09/04/2024 21:32
April 9 (Reuters) - Fusion Pharmaceuticals Inc FUSN.O :
* FUSION PHARMACEUTICALS ANNOUNCES PRESENTATION OF INTERIM
DATA
FROM THE PHASE 2 TATCIST CLINICAL TRIAL EVALUATING FPI-2265 AT
THE AACR ANNUAL MEETING 2024
* FUSION PHARMACEUTICALS INC - FPI-2265 PHASE 2 PORTION IS
EXPECTED TO BE INITIATED IN Q2 OF 2024
* FUSION PHARMACEUTICALS INC - FPI-2265 PHASE 3 GLOBAL
REGISTRATIONAL TRIAL IS EXPECTED TO BEGIN IN 2025
Source text for Eikon: ID:nCNWWpM95a
Further company coverage: FUSN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusion Pharmaceuticals
See all newsBrief: Acquisition Of Fusion Pharmaceuticals Completed
Brief: Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary